Seminari de Recerca "Genetic and pharmacological inhibition of SDCBP modulates stemness and chemoresistance in head and neck squamous cell carcinoma"

  Sala d’actes de la planta baixa de l'edifici Collserola del VHIR — See in map
01/03/2023 -- From 12:00h to 13:00h
Organize :
Recerca Vall d'Hebron
Modality: Presencial
Share it:

Speaker: Cristina Mir Pérez, Biomedical Research in Cancer Stem Cells - Vall d'Hebron Institute of Research (VHIR)

Introduction: Drug resistance is the principal limiting factor to achieving good survival rates in patients with cancer. The identification of potential biomarkers for diagnosis and prognostic prediction, as well as the design of new molecular-targeted treatments, will be essential to improving head and neck squamous cell carcinoma (HNSCC) patient outcomes.
Aim: The sensitization of resistant cells and cancer stem cells (CSCs) by inhibiting crucial proteins involved in cancer resistance.
Methods: To characterize the mechanisms that govern chemoresistance, we performed a comparative proteomic study analyzing HNSCC cells: CCL-138 (parental), CCL-138-R (cisplatin-resistant), and CSCs. Syntenin-1 (SDCBP) was upregulated in CCL-138-R cells and CSCs over parental cells. 
Results: On the one hand, SDCBP depletion sensitized biopsy-derived and established HNSCC cell lines to cisplatin (CDDP) and reduced CSC markers, being Src activation the main SDCBP downstream target. In mice, SDCBP-depleted cells formed tumors with decreased mitosis, Ki-67 positivity, and metastasis over controls. Moreover, the fusocellular pattern of JHU029-R cell-derived tumors reverted to a more epithelial morphology upon SDCBP silencing. Importantly, SDCBP expression was associated with Src activation, poor differentiated tumor grade, advanced tumor stage, and shorter survival rates in a series of 382 HNSCC patients.
On the other hand, through a virtual screening, sixteen new SDCBP ligands have been identified as candidates for HNSCC therapy.
Conclusions: Our results reveal that genetic and pharmacological targeting of SDCBP could be a potential therapeutic strategy to effectively eliminate CSCs and CDDP resistant tumors.

CV: After the Biomedicine bachelor degree in the Autonomous University of Barcelona (UAB),  Cristina Mir studied the Translational Biomedical Research Master degree in the Vall d'Hebron Research Institute (UAB-VHIR). Currently, she is enrolled in the medicine and translational research PhD programme of the University of Barcelona (UB), with the thesis title "Study of resistance to drugs in Head and neck squamous cell carcinoma (HNSCC)", developed in the Biomedical Research in Cancer Stem Cells group and directed by Dr. Lleonart. 

Host: Dr. Matilde Lleonart Pajarin, Biomedical Research in Cancer Stem Cells - Vall d'Hebron Institute of Research (VHIR)

Register here:

Related activities

Jornada de Cáncer de cérvix localmente avanzado: Perspectivas en el manejo terapéutico

06/02/2023 - 09:00
Médicos especialistas y residentes de oncología radioterápica, oncología médica y ginecología, radiología y medicina nuclear, Enfermería, residentes especialistas de Física y Protección Radiológica .
More information

V Jornada Infección y Terapias biológicas

06/12/2023 - 09:00
Médicos (facultativos y residentes) y Farmacéuticos que pautan terapias biológicas
More information

Curso de Aspectos claves para mejorar la vacunación en migrantes recién llegado

Edificio ICS Balmes C/ Gran Vía de les Corts Catalanes, 587, C/ de Balmes, 20. CP 08006, Barcelona
06/12/2023 - 16:00
Profesionales que trabajan con migrantes tanto en el ámbito sanitario como en lo social. Cómo: -Personas que trabajan en temas de Salud Pública tanto a nivel local como nacional -Personal que desarrolla sus funciones en centros de migrantes y centros de vacunación -Mediadores culturales -Trabajadores/as sociales -Personas que trabajan en áreas relacionadas con migración -Profesionales sanitarios (médicos; enfermeros/as; otros)
More information

Vacunas 2023 - XXVII Curso de Actualización en Inmunizaciones (presencial y virtual)

09/14/2023 - 09:00
More information

Subscribe to our newsletters and be a part of Vall d'Hebron Campus

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Vall d’Hebron University Hospital Foundation – Research Institute.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.